Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer
01 nov. 2016 16h30 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug...
TESARO Announces Presentation of Niraparib Data at the 2016 IGCS Biennial Meeting
31 oct. 2016 08h00 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of data from the ENGOT-OV16/NOVA trial...
TESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMA
27 oct. 2016 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
TESARO Announces Participation in Three Investor Conferences
24 oct. 2016 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences....
Tesaro to Announce Third-Quarter 2016 Financial Results on November 3, 2016
20 oct. 2016 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S....
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
08 oct. 2016 02h15 HE
|
TESARO, Inc.
Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...
TESARO and Zai Lab Announce Collaboration, Development and License Agreement
29 sept. 2016 07h01 HE
|
TESARO, Inc.
Collaboration enables the clinical development of niraparib in China by Zai Lab TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs...
TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission
12 sept. 2016 08h01 HE
|
TESARO, Inc.
WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
TESARO Announces Six Data Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting
06 sept. 2016 08h01 HE
|
TESARO, Inc.
Phase 3 results from ENGOT-OV16/NOVA trial of niraparib accepted for oral presentation during Presidential Symposium and inclusion in ESMO Press ProgrammeTESARO to webcast Investor and Analyst...
TESARO Announces Participation at Four Investor Conferences
24 août 2016 16h15 HE
|
TESARO, Inc.
WALTHAM, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences....